European Heart Journal Advance Access published online on January 6, 2006
European Heart Journal, doi:10.1093/eurheartj/ehi697
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 First Department of Medicine (Cardiology), University Hospital Mannheim, Theodor-Kutzer-Ufer 1-3, D-68167 Mannheim, Germany
* To whom correspondence should be addressed. Calcific aortic stenosis, with a prevalence of 3-9%, is the most frequent heart valve disease and the main cause for valve replacement in patients over 60 years of age. Once thought to be caused by a passive calcium precipitate within the aortic valve leaflets, there is now increasing evidence that development and progression of calcific aortic valve disease may be triggered by underlying genetic and cardiovascular risk factors, and is regulated by an active cellular process involving inflammatory pathways. Targeted drug therapy to prevent the progression of calcific aortic valve disease should ideally be based on the knowledge of risk factors and the molecular pathogenesis of the disease. Conflicting data exists on the potency of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (i.e. statins) to influence both risk factors and inflammatory pathways by lowering lipid levels and exerting anti-inflammatory properties, respectively. In this review, various aspects of the molecular pathogenesis of calcific aortic stenosis will be summarized and connected with recent experimental and clinical studies that address the potential benefit of the targeted drug therapy by statins in order to prevent the progression of the disease.
Received October 12, 2005
Revised November 17, 2005
Accepted December 1, 2005
Review
Statin therapy of calcific aortic stenosis: hype or hope?
Volker Liebe 1,
Martina Brueckmann 1,
Martin Borggrefe 1,
and
Jens J. Kaden 1 *
Jens J. Kaden, E-mail: jens.kaden{at}med.ma.uni-heidelberg.de
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K Akat, M Borggrefe, and J J Kaden Aortic valve calcification: basic science to clinical practice Heart, April 1, 2009; 95(8): 616 - 623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Parolari, C. Loardi, L. Mussoni, L. Cavallotti, M. Camera, P. Biglioli, E. Tremoli, and F. Alamanni Nonrheumatic calcific aortic stenosis: an overview from basic science to pharmacological prevention Eur. J. Cardiothorac. Surg., March 1, 2009; 35(3): 493 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Matsumoto, V. Adams, C. Walther, C. Kleinecke, P. Brugger, A. Linke, T. Walther, F. W. Mohr, and G. Schuler Reduced number and function of endothelial progenitor cells in patients with aortic valve stenosis: a novel concept for valvular endothelial cell repair Eur. Heart J., February 1, 2009; 30(3): 346 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Monzack, X. Gu, and K. S. Masters Efficacy of Simvastatin Treatment of Valvular Interstitial Cells Varies With the Extracellular Environment Arterioscler Thromb Vasc Biol, February 1, 2009; 29(2): 246 - 253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Kaden and D. Haghi Hypertension in aortic valve stenosis--a Trojan horse Eur. Heart J., August 2, 2008; 29(16): 1934 - 1935. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Bratos-Perez, P. L. Sanchez, S. Garcia de Cruz, E. Villacorta, I. F. Palacios, J. M. Fernandez-Fernandez, S. Di Stefano, A. Orduna-Domingo, Y. Carrascal, P. Mota, et al. Association between self-replicating calcifying nanoparticles and aortic stenosis: a possible link to valve calcification Eur. Heart J., February 1, 2008; 29(3): 371 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Lindgren, M Buxton, T Kahan, N R Poulter, B Dahlof, P S Sever, H Wedel, B Jonsson, and on behalf of the ASCOT trial investigators* Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen Heart, February 1, 2008; 94(2): e4 - e4. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Goldbarg, S. Elmariah, M. A. Miller, and V. Fuster Insights Into Degenerative Aortic Valve Disease J. Am. Coll. Cardiol., September 25, 2007; 50(13): 1205 - 1213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Kaden Towards medical therapy of calcific aortic stenosis lessons from molecular biology Eur. Heart J., August 1, 2007; 28(15): 1795 - 1796. [Full Text] [PDF]
|
|
|
|
|
|
P. Lindgren, J. Graff, A. G. Olsson, T. J. Pedersen, B. Jonsson, and on behalf of the IDEAL Trial Investigators Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin Eur. Heart J., June 2, 2007; 28(12): 1448 - 1453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Chua and K. Kalb Statins and Progression of Calcified Aortic Stenosis Ann. Pharmacother., December 1, 2006; 40(12): 2195 - 2199. [Abstract] [Full Text] [PDF]
|
|